文献速递脊柱关节炎类风湿关节炎

银屑病关节炎与中轴型脊柱关节炎中TNF抑制剂剂量调整(TAPAS):回顾性队列研究

Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

结果显示DAGDO期与稳定剂量期DAS28-CRP和BASDAI较全剂量维持期无显著差异,而平均%DDD由108%降至62%。

要点

  • DAGDO期与全剂量维持期相比,DAS28-CRP差值0.06(95%CI:-0.09,0.21),无显著差异。
  • DAGDO期与全剂量维持期相比,BASDAI差值0.03(95%CI:-0.21,0.27),无显著差异。
  • PsA与axSpA的%DDD均从108%降至62%,优化后稳定期回升至78%和72%。

核心结论

  • 对病情稳定且符合TNFi DAGDO条件的PsA和axSpA患者,DAGDO可减少药物暴露且与全剂量维持相比不损害疾病活动度。

研究设计与样本

  • 划分全剂量维持期、TNFi DAGDO期及DAGDO后稳定剂量期三个治疗期,采用混合模型分析DAS28-CRP与BASDAI。
  • PsA与axSpA的中位随访时间分别为46个月和44个月,DAS28-CRP平均测量6.5次、BASDAI平均测量6.4次。

主要发现

  • 与全剂量维持期相比,DAGDO期DAS28-CRP校正差值0.06(95%CI:-0.09,0.21),稳定剂量期0.03(95%CI:-0.14,0.20)。
  • 与全剂量维持期相比,DAGDO期BASDAI差值0.03(95%CI:-0.21,0.27),稳定剂量期0.05(95%CI:-0.24,0.34)。
  • 三个治疗期的平均%DDD在PsA为108%、62%、78%,在axSpA为108%、62%、72%。

关键数值与推荐

  • PsA的DAS28-CRP校正差值0.06(95%CI:-0.09,0.21),axSpA的BASDAI差值0.03(95%CI:-0.21,0.27),均以全剂量维持期为参照。
  • PsA三个治疗期平均%DDD分别为108%、62%、78%,axSpA分别为108%、62%、72%。

临床怎么用

  • 对TNFi治疗下处于低疾病活动度的PsA和axSpA患者,可考虑按疾病活动度导向逐步减量以降低药物暴露。
  • 减量期间应持续监测DAS28-CRP或BASDAI,以确认疾病活动度未因减量而升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated the effect of disease activity-guided dose optimization (DAGDO) of TNF inhibitor (TNFi) on disease activity and TNFi dose in PsA and axial spondyloarthritis (axSpA) patients with low disease activity (LDA). METHODS: A retrospective cohort study was conducted in PsA and axSpA patients doing well on TNFi and eligible for TNFi DAGDO. Three different treatment periods were defined: (i) full dose continuation period, (ii) TNFi DAGDO period, and (iii) period with stable TNFi dose after DAGDO. A mixed-model analysis was used to estimate mean Disease Activity Score 28-joint count CRP (DAS28-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) during these periods, and a mean percentage of the daily defined dose (%DDD) was calculated as secondary outcome. RESULTS: Three hundred and twenty-four patients (153 PsA and 171 axSpA) were included, with a mean of 6.5 DAS28-CRP and 6.4 BASDAI measurements and a median follow-up duration of 46 and 44 months, respectively. A corrected difference of 0.06 (95% CI: -0.09, 0.21) in mean DAS28-CRP was found for the TNFi DAGDO period and 0.03 (95% CI: -0.14, 0.20) for the period with stable TNFi dose, compared with full dose continuation period. Differences for BASDAI were 0.03 (95% CI: -0.21, 0.27) and 0.05 (95% CI: -0.24, 0.34), respectively. The mean %DDD for the three treatment periods was for PsA 108%, 62% and 78%, and for axSpA 108%, 62% and 72%, respectively. CONCLUSION: DAGDO of TNFi reduces drug exposure and has no negative effects on disease activity in PsA and axSpA patients compared with full dose continuation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Michielsens CAJ, den Broeder N, Mulder MLM, et al. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. Rheumatology (Oxford). 2022. PMID: 34599803. doi:10.1093/rheumatology/keab741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。